Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP201
- Development stage
- Unknown
- Lead developer
- NIBEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
NP201 is a code name associated with two distinct investigational drug candidates. One is a biologic therapy developed by NGM Biopharmaceuticals, in collaboration with Merck & Co., for the treatment of metabolic diseases including type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). This candidate, later known as NGM313 and subsequently MK-3655, is a monoclonal antibody that acts as a selective agonist of the FGFR1/Klotho-beta receptor complex to improve insulin sensitivity and lipid metabolism. The second NP201 is a candidate developed by NuPathe (acquired by Teva Pharmaceutical Industries) for Parkinson's disease. This version utilizes NuPathe's proprietary Long-Acting Delivery (LAD) technology, consisting of a biodegradable subcutaneous implant designed to provide continuous, long-term delivery of the dopamine agonist ropinirole, aiming to reduce motor fluctuations and "off" time in Parkinson's patients.
- Other names
- LAD-ropinirole
02
Targets
KLB (Beta-Klotho)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on NP201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP201.